BioNTech SE
BNTX
$89.27
-$0.04-0.05%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 11.45% | 6.95% | 7.44% | 0.51% | -27.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 11.45% | 6.95% | 7.44% | 0.51% | -27.67% |
| Cost of Revenue | 19.84% | 17.34% | 26.88% | -0.26% | -9.92% |
| Gross Profit | 9.41% | 5.02% | 3.43% | 0.71% | -30.99% |
| SG&A Expenses | 9.58% | -9.56% | -11.02% | 2.72% | 7.41% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | 34.10% | 298.37% | 323.07% | 243.64% | 238.50% |
| Total Operating Expenses | 8.21% | 16.92% | 17.86% | 49.77% | 63.20% |
| Operating Income | -1.24% | -86.07% | -86.48% | -2,339.61% | -196.36% |
| Income Before Tax | -58.69% | -69.83% | -61.72% | -650.71% | -157.56% |
| Income Tax Expenses | 796.32% | -64.47% | -117.38% | -181.54% | -105.44% |
| Earnings from Continuing Operations | -76.39% | -26.46% | 29.76% | -786.05% | -171.78% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -76.39% | -26.46% | 29.76% | -786.05% | -171.78% |
| EBIT | -1.24% | -86.07% | -86.48% | -2,339.61% | -196.36% |
| EBITDA | 0.05% | -72.41% | -105.15% | -598.51% | -170.23% |
| EPS Basic | -75.18% | -26.18% | 29.71% | -772.17% | -172.03% |
| Normalized Basic EPS | -73.72% | -102.56% | -52.09% | -451.17% | -146.86% |
| EPS Diluted | -74.54% | -24.67% | 29.99% | -809.59% | -173.11% |
| Normalized Diluted EPS | -72.97% | -97.03% | -47.68% | -466.27% | -147.62% |
| Average Basic Shares Outstanding | 0.26% | -0.09% | 0.36% | 0.17% | -0.03% |
| Average Diluted Shares Outstanding | -0.05% | -0.53% | 0.16% | -0.03% | -0.47% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |